RxDoctor Payments Data

Eugene Holuka, MD

Internal Medicine · Staten Island, NYNPI 1013902550

Payments from drug & device makers

$56,413in general payments, 2019–2025

Across 10 payments — averaging $5641.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Citius Pharmaceuticals, Inc.$56K
  • Abbott$152
  • Amgen$106
  • Procept Biorobotics Corporation$87
  • AstraZeneca$22
  • Sanofi Pasteur Inc.$18
  • plus $28 from 2 others

What the payments were for

  • Speaking & faculty fees$56,00099%
  • Food & beverage$4131%

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Citius Pharmaceuticals, Inc.3$56,000
Abbott1$152
Amgen1$106
Procept Biorobotics Corporation1$87
AstraZeneca1$22
Sanofi Pasteur Inc.1$18
Novartis1$15
Gilead1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,413 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$150,818
Medicare patients
314
Services billed
1,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate67$214,026
OzempicSemaglutide183$194,550
EliquisApixaban137$175,230
JanuviaSitagliptin Phosphate71$83,565
Metformin Er GastricMetformin Hcl13$71,233
JardianceEmpagliflozin42$64,340
JanumetSitagliptin Phos/Metformin Hcl61$63,270
XareltoRivaroxaban39$48,845
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$41,784
Diclofenac Sodium152$41,591
EntrestoSacubitril/Valsartan22$40,186
MeloxicamMeloxicam, Submicronized22$39,117
TrulicityDulaglutide35$38,621
Lactulose20$38,089
LinzessLinaclotide22$23,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya$13$41,78411 claims
NovartisEntresto$15$40,18622 claims
AstraZenecaFarxiga$22$20,50815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →